ClinicalTrials.gg
CompletedNCT02865356CYCLATOPUpdated Apr 17, 2018

Topical Solution for the Treatment of Atopic Dermatitis

A Phase 2 interventional study of Cyclosporine 5% solution and Placebo in Atopic Dermatitis, sponsored by Spherium Biomed. Completed at 9 sites in Spain. Open to participants aged 2 Years to 75 Years. Per ClinicalTrials.gov, last updated 2018-04-17.

Sponsored by Spherium Biomed · Phase 2, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
36
Allocation
Randomized
Ages
2 Years to 75 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-16

Among 11 studies testing cyclosporine in Dermatitis, Atopic — 1 open to participants now, 1 under way, none of them phase 3. Cyclosporine · Dermatitis, Atopic.

Started
2016
the only one that year
Phase 2
2 of 11
none open now
Registered
7th of 11
by date
Lead sponsor
1 of 11
Spherium Biomed

Among the 11 studies testing cyclosporine in Dermatitis, Atopic, this one is the only one that started in 2016, is one of 2 in phase 2, and was the 7th registered.

Dermatitis, Atopic

1,594 studies on the registry are indexed under Dermatitis, Atopic; 287 are open to participants now.

Browse Dermatitis, Atopic studies →

Open to participants now

1 of the 11 studies testing cyclosporine in Dermatitis, Atopic is open now, in 1 country. Recruiting first, the newest first:

By country, each count listing its studies:

About cyclosporine

Cyclosporine: first FDA approval 1983 (SANDIMMUNE), first EMA approval 2015. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 195 Dermatitis, Atopic studies recruiting now, 83 (43%) set no upper age limit and 96 (49%) stop at 75 or younger; 94 take children under 18; 52 take healthy volunteers.

This study: 2 Years to 75 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 11 studies testing cyclosporine in Dermatitis, Atopic, or all of them as a file.
02

Study summary

The study is designed as a proof of concept, multi-center, randomized, double-blind and vehicle-controlled study with intra-individual comparison of treatments.

Three age cohorts of patients will be included in the study according to the following age ranges:

  1. ≥18 years old (minimum 6, maximum 18 patients)
  2. >12 - 17 years old (minimum 6, maximum 18 patients)
  3. >2 - 12 years old (minimum 6, maximum 18 patients)

The main objectives of study are:

To assess the efficacy of SP14019-F-01 topical solution (5% cyclosporine A [CsA]) compared to placebo topical solution for the treatment of patients with mild to moderate atopic dermatitis (AD).

To evaluate the safety and tolerability of SP14019-F-01 (5% CsA) topical solution in patients with mild to moderate AD.

Read the detailed description

The study is designed as a proof of concept, multi-center, randomized, double-blind and vehicle-controlled study with intra-individual comparison of treatments. CsA plasma concentration assessments will be carried out at Visit 0 predose, and Visits 1 and 4 of the study period.

Three age cohorts of patients will be included in the study according to the following age ranges:

  1. ≥18 years old (minimum 6, maximum 18 patients)
  2. >12 - 17 years old (minimum 6, maximum 18 patients)
  3. >2 - 12 years old (minimum 6, maximum 18 patients) The study will close when the total of 36 patients has been included among all age groups and the minimum number of 6 patients has been reached for each age group.

Before including paediatric population, a minimum of 6 adult patients should complete the treatment to assess the safety profile.

A randomized list will be created to determine in which side of the body (left or right) the subject will apply each medication (SP14019-F-01 topical solution [5% CsA] or SP14019-F-02 vehicle-control placebo solution). Solutions will be applied twice daily for four complete weeks (28 days) in all affected areas.

Photography will be used to record the evolution of the lesions at Visits 0 (pre-1st dose), Visits 1, 2, 3, 4 and follow-up.

The main objectives of study are:

To assess the efficacy of SP14019-F-01 topical solution (5% cyclosporine A [CsA]) compared to placebo topical solution for the treatment of patients with mild to moderate atopic dermatitis (AD).

To evaluate the safety and tolerability of SP14019-F-01 (5% CsA) topical solution in patients with mild to moderate AD.

A Steering Committee will convene periodically to maintain the quality of study conduct, and to discuss any major issues or concerns and with particular attention to some critical events which may lead to stop the recruitment. These critical events are the observation of either new unexpected signals on safety related to CsA. The Steering Committee will also evaluate the safety profile of the treatment before including paediatric population

03

Conditions studied

  • Atopic Dermatitis

Keywords

  • atopic dermatitis
  • eczema
  • children
  • skin
  • topical
  • cyclosporine
04

Who can participate

Ages eligible
2 Years to 75 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Male or female aged between 2 and 75 years, inclusive, at the screening visit. 2. AD diagnosis according to the Hanifin/Rajka criteria with one eczema outbreak at the screening and baseline.

    1. Presence of at least two lesional areas. These areas should be at the left and right side of the body and occupying a body surface area (BSA) in each side between 0.1% and 10% of the BSA. IGA score of the two sites not differ by more than 1 point.
    1. Mild to moderate disease severity of AD defined by an IGA score of 2 or 3 at baseline (IGA scale from 0 to 4).
    1. Total BSA of AD involvement ≤ 10% in each side of the body (≤ 20% maximum). 6. Normal weight as defined by a Quetelet Index ( [BMI]: weight in kg divided by the square of height in meters) of 18.0 to 30.0 kg/m2 (both included).
    1. General medical condition, in the investigator's opinion, does not interfere with the assessments and the completion of the trial.
    1. Parent's or legal guardian's written and child assent, if appropriate or patient's inform consent for patients ≥ 18 years of age before any assessment is performed.
    1. Able to communicate with the investigator and comply with the requirements of the study (for children the parent can assist when necessary).

Exclusion criteria

Exclusion Criteria:

    1. Female subject of without use of effective methods, or not willing to continue practicing these birth control methods for at least 30 days after the end of the treatment period;

Note: Estrogen based hormonal contraception may not be reliable when SP14019-F-01 topical solution is applied, therefore to be eligible for this trial, women of childbearing potential should either:

  1. use a double barrier method to prevent pregnancy (i.e., using a condom with either diaphragm or cervical cap);
  2. use hormonal based contraceptives in combination with a barrier contraceptive (i.e., male condom, diaphragm or cervical cap, or female condom);
  3. use an intrauterine device in combination with a barrier contraceptive (i.e., male condom, diaphragm or cervical cap, or female condom);
  4. be only non-heterosexually active, practice heterosexual abstinence, or have a vasectomized partner (confirmed sterile). Women with tubal ligation are required to use 1 non-hormonal contraceptive method.

    Women who are for at least 2 years, and women with total hysterectomy are considered of non-childbearing potential. Males with partners of childbearing potential should inform them of their participation in this clinical study and use a highly effective method of birth control during the study.

    1. Pregnant woman or with a positive pregnancy test or breast feeding at baseline.
    1. Any condition in the lesions that in the opinion of the investigator could interfere with clinical assessments, e.g. acne, infection, rash other than AD, sunburn, scars, hairy or tattooed area.
    1. Patients receiving phototherapy or systemic therapy for AD within 4 weeks before the first application of trial medication.
    1. Patients receiving antibiotics, topical therapy for AD within 2 weeks before the first application of trial medication.
    1. Patients taking antihistamines within 1 week before the first application of trial medication.
    1. Patients receiving radiation therapy, systemic therapy with cytostatics or biological therapy within 24 weeks before the first application of trial medication, or with previous history of (excluding basal cell carcinoma).
    1. Patients with any acute skin infection (superinfection or secondary impetiginisation).
    1. Patients with confirmed hypertension, renal disease or serious infections at screening.
    1. Any currently active allergy such as but not limited to drug allergy, food allergy or hay fever.
    1. Previously demonstrated allergy or to any of the of the trial medication administered in this trial.
    1. Participation in an drug trial within 30 days prior to the first application of trial medication.
    1. Any condition (including but not limited to alcohol and drug use), which in the opinion of the investigator could compromise the patient safety or compliance with trial procedures.
    1. Subjects who have received or are planning to receive any vaccination within 28 days prior to the first dose of study medication, or planning to receive a vaccination during the course of the study.
Terms in these criteria, in plain language(10)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Postmenopausal

Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Excipients

The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Triple (Participant, Care provider, Investigator)
Enrollment
36 participants (actual)

Study arms

  • Experimental
    Cyclosporine 5% Solution

    SP14019-F-01 Cyclosporine solution, 5%. Cyclosporine solution will be applied twice daily for four complete weeks (28 days) in all affected areas. A randomized list will be created to determine in which side of the body (left or right) the subject will apply each medication

    Drug: Cyclosporine 5% solution

  • Placebo comparator
    Placebo

    SP14019-F-02 vehicle-control placebo solution. Vehicle-control placebo solution will be applied twice daily for four complete weeks (28 days) in all affected areas. A randomized list will be created to determine in which side of the body (left or right) the subject will apply each medication

    Drug: Placebo

Interventions

  • topical solution

    Also known as: ciclosporin

  • DrugPlacebo

    topical vehicle solution

    Also known as: SP14019-F-02 Placebo

06

What researchers measure

Primary outcomes

  1. Absolute change from baseline (Day 0) of Eczema Area and Severity Index (EASI) score of the treated body area (CsA vs Vehicle control placebo)

    Time frame: Absolute change from Day 0 (baseline) to Day 7 (Visit 1), Day 14 (Visit 2), Day 21(Visit 3) and Day 28 (Visit 4).

  2. Change from baseline (Day 0) of Investigator's Global Assessment (IGA) score (on a 0 to 4-point scale; CsA vs Vehicle control placebo)

    Time frame: Absolute change from Day 0 (baseline) to Day 7 (Visit 1), Day 14 (Visit 2), Day 21(Visit 3) and Day 28 (Visit 4).

  3. Absolute change from baseline (Day 0) of Atopic Dermatitis Severity Index (ADSI) score (Cs vs Vehicle control placebo)

    Time frame: Absolute change from Day 0 (baseline) to Day 7 (Visit 1), Day 14 (Visit 2), Day 21(Visit 3) and Day 28 (Visit 4).

Secondary outcomes

  1. Frequency and severity of treatment-emergent adverse events (TEAEs).

    Time frame: From date of randomization (Day 0) until 6 weeks

  2. Frequency and severity of TEAEs leading to study drug discontinuation

    Time frame: From date of randomization (Day 0) until 6 weeks

  3. CsA plasma concentrations

    samples obtained just before the first daily dose (around 8 am) on Visits 0, 1 and 4 to check the absence of systemic absorption during the period of treatment.

    Time frame: From date of randomization (Day 0) up to 4 weeks, on day 7 and 28.

07

Study locations

9 sites
  • Hospital Universitario Germans Trias i Pujol
    Badalona, Barcelona 08916, Spain
  • Hospital Sant Joan de Déu
    Esplugues de Llobregat, Barcelona 08950, Spain
  • Hospital General Universitario de Alicante
    Alicante, 03010, Spain
  • Hospital del Mar
    Barcelona, 08003, Spain
  • Hospital Universitario de La Princesa
    Madrid, 28006, Spain
  • Hospital Infantil Universitario Niño Jesús
    Madrid, Spain
  • Hospital Universitario Virgen de la Victoria
    Málaga, 29010, Spain
  • Hospital Universitario Virgen Macarena
    Sevilla, 41009, Spain
  • Hospital Universitari i Politècnic La Fe
    Valencia, 46026, Spain
08

References and documents

Individual participant data

Plan to share: Undecided

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Sep 2016, a primary completion of Apr 2017 and a completion of Apr 2017. It does not say whether these dates are actual or estimated.

How these figures are worked out, and which studies are left out of them.

Registered
Aug 4, 2016
First posted
Aug 12, 2016
Start
Sep 2016
Primary completionActual
Apr 12, 2017
CompletionActual
Apr 12, 2017
Last update
Apr 17, 2018
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Apr 17, 2018, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT02865356
Lead sponsor
Spherium Biomed
Collaborators
Germans Trias i Pujol Hospital, Hospital del Mar, Hospital Sant Joan de Deu, Hospital Universitario Virgen Macarena, Hospital Universitario La Fe, Hospital General Universitario de Alicante, Fundación de Investigación Biomédica - Hospital Universitario de La Princesa, Hospital Universitario Virgen de la Victoria, Hospital Infantil Universitario Niño Jesús, Madrid, Spain
Responsible party
Sponsor
First posted
Aug 12, 2016
Start date
Sep 2016
Primary completion
Apr 12, 2017
Completion
Apr 12, 2017
Last update
Apr 17, 2018

Study contacts

Carlos Ferrándiz, MD, PhD
principal investigator · Germans Trias i Pujol Hospital

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Apr 2018. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Cyclosporine

Start the discussion